Skip to main content

Advertisement

Log in

Age is a major determinant for poor prognosis in patients with pilocytic astrocytoma: a SEER population study

  • Original Article
  • Published:
Clinical and Experimental Medicine Aims and scope Submit manuscript

Abstract

Background Pilocytic astrocytomas (PAs) are central nervous system tumors with variable prognosis and poorly understood risk factors. Little evidence exists regarding the effect of age on mortality in PA. Therefore, we conducted a thorough characterization of PA in the US. Methods We queried the Surveillance, Epidemiology, and End Results (SEER) database between 2000 and 2018 to extract age-adjusted incidence rate (AAIR), age-adjusted mortality rate (AAMR), and survival data on PA. The age group comparisons for each measure varied depending on available SEER data. We compared trends in AAIR and AAMR by two age groups (children, 0–19 years; adults, 20 + years) and by sex. The cumulative incidence function and the Fine-Gray competing risk model were applied by 0–19, 20–39, 40–59, and 60 + years of age groups. Results This study included 5211 incident PA and 462 PA-specific deaths between 2000 and 2018. Trends in AAIRs and AAMRs were almost constant between 2000 and 2018. Average AAIRs had a sharp peak in 1–4 years of age groups, whereas AAMRs had a gradual peak in 80–84 years of age groups. Age groups, tumor location, and race/ethnicity were significantly associated with PA-specific death, whereas only age was associated with other cause of deaths. Conclusions Trends in AAIRs and AAMRs were constant regardless of age. PAs in older populations, especially over 60 years old, have higher incidence of death than those in younger populations.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

Abbreviations

AAIR:

Age-adjusted incidence rate

AAMR:

Age-adjusted mortality rate

AAPC:

Average annual percentage change

CODs:

Cause of deaths

MC AAP:

Methylation class with anaplastic astrocytoma with piloid features

MIR:

Mortality-to-incidence ratio

PA:

Pilocytic astrocytoma

SEER:

The Surveillance, Epidemiology, and End results

SHR:

Subdistribution hazard ratio

WHO:

World Health Organization

References

  1. Louis DN, Perry A, Wesseling P, et al. The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro Oncol. 2021;23:1231–51. https://doi.org/10.1093/neuonc/noab106.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Ostrom QT, Patil N, Cioffi G, Waite K, Kruchko C, Barnholtz-Sloan JS. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2013–2017. Neuro Oncol. 2020;22:iv1–96. https://doi.org/10.1093/neuonc/noaa200.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Capper D, Jones DTW, Sill M, et al. DNA methylation-based classification of central nervous system tumours. Nature. 2018;555:469–74. https://doi.org/10.1038/nature26000.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Hasselblatt M, Riesmeier B, Lechtape B, et al. BRAF-KIAA1549 fusion transcripts are less frequent in pilocytic astrocytomas diagnosed in adults. Neuropathol Appl Neurobiol. 2011;37:803–6. https://doi.org/10.1111/j.1365-2990.2011.01193.x.

    Article  CAS  PubMed  Google Scholar 

  5. Reinhardt A, Stichel D, Schrimpf D, et al. Anaplastic astrocytoma with piloid features, a novel molecular class of IDH wildtype glioma with recurrent MAPK pathway, CDKN2A/B and ATRX alterations. Acta Neuropathol. 2018;136:273–91. https://doi.org/10.1007/s00401-018-1837-8.

    Article  CAS  PubMed  Google Scholar 

  6. Voronina N, Aichmüller C, Kolb T, et al. The age of adult pilocytic astrocytoma cells. Oncogene. 2021;40:2830–41. https://doi.org/10.1038/s41388-021-01738-0.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Tabash MA. Characteristics, survival and incidence rates and trends of pilocytic astrocytoma in children in the United States SEER-based analysis. J Neurol Sci. 2019;400:148–52. https://doi.org/10.1016/j.jns.2019.03.028.

    Article  PubMed  Google Scholar 

  8. Haifler M, Neheman A, Zisman A. Has stage migration in renal cancer run its course? A SEER database analysis. Clin Genitourin Cancer. 2020;18:e368–73. https://doi.org/10.1016/j.clgc.2020.01.005.

    Article  PubMed  Google Scholar 

  9. Hallowell BD, Endeshaw M, McKenna MT, Senkomago V, Razzaghi H, Saraiya M. Cancer mortality rates among US and foreign-born individuals: United States 2005–2014. Prev Med. 2019;126: 105755. https://doi.org/10.1016/j.ypmed.2019.105755.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Tomita Y, Tanaka Y, Takata N, Hibler EA, Hashizume R, Becher OJ. Fifteen-year trends and differences in mortality rates across sex, age, and race/ethnicity in patients with brainstem tumors. Neurooncol Adv. 2021;3:vdab137. https://doi.org/10.1093/noajnl/vdab137.

    Article  PubMed  PubMed Central  Google Scholar 

  11. Kleihues P, Louis DN, Scheithauer BW, et al. The WHO classification of tumors of the nervous system. J Neuropathol Exp Neurol. 2002;61:215–25. https://doi.org/10.1093/jnen/61.3.215 (Discussion 226-219).

    Article  PubMed  Google Scholar 

  12. Chu KC, Miller BA, Feuer EJ, Hankey BF. A method for partitioning cancer mortality trends by factors associated with diagnosis: an application to female breast cancer. J Clin Epidemiol. 1994;47:1451–61. https://doi.org/10.1016/0895-4356(94)90089-2.

    Article  CAS  PubMed  Google Scholar 

  13. Sunkara V, Hébert JR. The colorectal cancer mortality-to-incidence ratio as an indicator of global cancer screening and care. Cancer. 2015;121:1563–9. https://doi.org/10.1002/cncr.29228.

    Article  PubMed  Google Scholar 

  14. Clegg LX, Hankey BF, Tiwari R, Feuer EJ, Edwards BK. Estimating average annual per cent change in trend analysis. Stat Med. 2009;28:3670–82. https://doi.org/10.1002/sim.3733.

    Article  PubMed  PubMed Central  Google Scholar 

  15. Best B, Nguyen HS, Doan NB, et al. Causes of death in glioblastoma: insights from the SEER database. J Neurosurg Sci. 2019;63:121–6. https://doi.org/10.23736/s0390-5616.18.04599-x.

    Article  PubMed  Google Scholar 

  16. Johnson DR, Brown PD, Galanis E, Hammack JE. Pilocytic astrocytoma survival in adults: analysis of the surveillance, epidemiology, and end results program of the national cancer institute. J Neurooncol. 2012;108:187–93. https://doi.org/10.1007/s11060-012-0829-0.

    Article  PubMed  Google Scholar 

  17. Collins VP, Jones DT, Giannini C. Pilocytic astrocytoma: pathology, molecular mechanisms and markers. Acta Neuropathol. 2015;129:775–88. https://doi.org/10.1007/s00401-015-1410-7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Louis DN, Ohgaki H, Wiestler OD, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007;114:97–109. https://doi.org/10.1007/s00401-007-0243-4.

    Article  PubMed  PubMed Central  Google Scholar 

  19. Yazdanyar A, Newman AB. The burden of cardiovascular disease in the elderly: morbidity, mortality, and costs. Clin Geriatr Med. 2009;25(563–577):vii. https://doi.org/10.1016/j.cger.2009.07.007.

    Article  PubMed  Google Scholar 

  20. Yang W, Porras JL, Khalafallah AM, Sun Y, Bettegowda A, Mukherjee D. Comparison of adult and pediatric pilocytic astrocytomas using competing risk analysis: a population-based study. Clin Neurol Neurosurg. 2022;212: 107084. https://doi.org/10.1016/j.clineuro.2021.107084.

    Article  PubMed  Google Scholar 

  21. Becker AP, Scapulatempo-Neto C, Carloni AC, et al. KIAA1549: BRAF gene fusion and FGFR1 hotspot mutations are prognostic factors in Pilocytic Astrocytomas. J Neuropathol Exp Neurol. 2015;74:743–54. https://doi.org/10.1097/nen.0000000000000213.

    Article  CAS  PubMed  Google Scholar 

  22. Ogiwara H, Bowman RM, Tomita T. Long-term follow-up of pediatric benign cerebellar astrocytomas. Neurosurgery. 2012;70:40–7. https://doi.org/10.1227/NEU.0b013e31822ff0ed (Discussion 47-48).

    Article  PubMed  Google Scholar 

  23. Saunders DE, Phipps KP, Wade AM, Hayward RD. Surveillance imaging strategies following surgery and/or radiotherapy for childhood cerebellar low-grade astrocytoma. J Neurosurg. 2005;102:172–8. https://doi.org/10.3171/jns.2005.102.2.0172.

    Article  PubMed  Google Scholar 

  24. Bornhorst M, Frappaz D, Packer RJ. Pilocytic astrocytomas. Handb Clin Neurol. 2016;134:329–44. https://doi.org/10.1016/b978-0-12-802997-8.00020-7.

    Article  PubMed  Google Scholar 

  25. Yabuno S, Kawauchi S, Umakoshi M, et al. Spinal cord diffuse midline Glioma, H3K27M- mutant effectively treated with Bevacizumab: a report of two cases. NMC Case Rep J. 2021;8:505–11. https://doi.org/10.2176/nmccrj.cr.2021-0033.

    Article  PubMed  PubMed Central  Google Scholar 

  26. Cella DF, Orav EJ, Kornblith AB, et al. Socioeconomic status and cancer survival. J Clin Oncol. 1991;9:1500–9. https://doi.org/10.1200/JCO.1991.9.8.1500.

    Article  CAS  PubMed  Google Scholar 

  27. Carstam L, Ryden I, Gulati S, et al. Socioeconomic factors affect treatment delivery for patients with low grade glioma: a Swedish population-based study. J Neurooncol. 2020;146:329–37. https://doi.org/10.1007/s11060-019-03378-7.

    Article  CAS  PubMed  Google Scholar 

  28. Sherwood PR, Dahman BA, Donovan HS, Mintz A, Given CW, Bradley CJ. Treatment disparities following the diagnosis of an astrocytoma. J Neurooncol. 2011;101:67–74. https://doi.org/10.1007/s11060-010-0223-8.

    Article  PubMed  Google Scholar 

Download references

Funding

This study was supported by JSPS KAKENHI Grant to Y.O. (Nos. JP21K20803 and JP22K16687). Other authors certify that they have no grants, equipment, drugs, and other support that facilitated the conduct of the work described in the article or the writing of the article itself.

Author information

Authors and Affiliations

Authors

Contributions

YO contributed to the study concept and design. Data collection was performed by YT, and statistical analysis was conducted by YT and YT. The first draft of the manuscript was written by YT and YT, and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.

Corresponding authors

Correspondence to Yoshihiro Tanaka or Yoshihiro Otani.

Ethics declarations

Competing interests

The authors declare no competing interests.

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

This study utilized deidentified data from the SEER database that is a publicly available. This secondary analysis of deidentified data was reviewed and approved by the Okayama University ethics board.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Rights and permissions

Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Tomita, Y., Hibler, E.A., Suruga, Y. et al. Age is a major determinant for poor prognosis in patients with pilocytic astrocytoma: a SEER population study. Clin Exp Med 23, 2301–2309 (2023). https://doi.org/10.1007/s10238-022-00882-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10238-022-00882-5

Keywords

Navigation